{"schema_version":"secwatch.filing_event.v1","accession":"0001396814-22-000059","form_type":"8-K","ticker":"PCRX","cik":"0001396814","company_name":"Pacira BioSciences, Inc.","filed_at":"2022-10-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.440995+00:00","generated_at":"2026-06-23T03:47:01.191322+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Pacira reports preliminary Q3 2022 revenue of $167.5M, up 31% YoY; EXPAREL sales up 9%","bullets":["Preliminary unaudited Q3 2022 revenue $167.5M vs $127.7M in Q3 2021.","EXPAREL net sales $132.6M (Q3 2022) vs $121.9M (Q3 2021); average daily sales 109% of prior year.","ZILRETTA net sales $26.5M for Q3 2022; iovera° net sales $4.5M.","Company not providing 2022 revenue or gross margin guidance due to macro uncertainty.","Monthly intra-quarter revenue disclosure continues; weekly EXPAREL utilization data posted on investor site."],"urls":{"canonical":"https://secwatch.observer/filing/0001396814-22-000059","json":"https://secwatch.observer/filing/0001396814-22-000059.json","markdown":"https://secwatch.observer/filing/0001396814-22-000059.md","text":"https://secwatch.observer/filing/0001396814-22-000059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1396814/000139681422000059/0001396814-22-000059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1396814/000139681422000059/pcrx-20221013.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T03:47:01.191322+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}